General Information of Drug Therapeutic Target (DTT) (ID: TTTU72V)

DTT Name Steroid 5-alpha-reductase 1 (SRD5A1)
Synonyms SRD5A1; SR type 1; 5-alpha reductase 1
Gene Name SRD5A1
DTT Type
Clinical trial target
[1]
Related Disease
Prostate disease [ICD-11: GA91]
BioChemical Class
CH-CH donor oxidoreductase
UniProt ID
S5A1_HUMAN
TTD ID
T70309
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 1.3.1.22
Sequence
MATATGVAEERLLAALAYLQCAVGCAVFARNRQTNSVYGRHALPSHRLRVPARAAWVVQE
LPSLALPLYQYASESAPRLRSAPNCILLAMFLVHYGHRCLIYPFLMRGGKPMPLLACTMA
IMFCTCNGYLQSRYLSHCAVYADDWVTDPRFLIGFGLWLTGMLINIHSDHILRNLRKPGD
TGYKIPRGGLFEYVTAANYFGEIMEWCGYALASWSVQGAAFAFFTFCFLSGRAKEHHEWY
LRKFEEYPKFRKIIIPFLF
Function
Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5- alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
KEGG Pathway
( )
Reactome Pathway
Androgen biosynthesis (R-HSA-193048 )
BioCyc Pathway
MetaCyc:HS07261-MON

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
FR-146687 DMGO45I Prostate disease GA91 Phase 2 [1]
------------------------------------------------------------------------------------
3 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
MK-386 DM48ELZ Acne vulgaris ED80 Discontinued in Phase 2 [2]
AS-601811 DMINF80 Acne vulgaris ED80 Discontinued in Phase 1 [3], [1]
Bexlosteride DMH7YD4 N. A. N. A. Terminated [2]
------------------------------------------------------------------------------------
18 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid DMPHM23 Discovery agent N.A. Investigative [4]
(3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid DMX5CY3 Discovery agent N.A. Investigative [4]
(E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid DMOWGT3 Discovery agent N.A. Investigative [4]
1,2,5,6-tetrahydro pyrido[1,2-a]quinolin-3-one DM7BAU2 Discovery agent N.A. Investigative [5]
1-Methyl-5-(4-phenylazo-phenyl)-piperidin-2-one DM4HS92 Discovery agent N.A. Investigative [6]
1-Methyl-5-phenyl-piperidin-2-one DMB3JO2 Discovery agent N.A. Investigative [6]
2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol DMRVYKQ Discovery agent N.A. Investigative [7]
3,4,5,6-Tetrahydrobenzo[c]quinolizin-3-(4aH)-one DMKOE9I Discovery agent N.A. Investigative [5]
4,4'-dihydroxyoctafluoroazobenzene DM1ONBT Discovery agent N.A. Investigative [7]
4-(4-phenoxybenzoyl)benzoic acid DMOHB6U Discovery agent N.A. Investigative [4]
4-Methyl-5,6-dihydro-pyrido[1,2-a]quinolin-3-one DM7LPON Discovery agent N.A. Investigative [5]
4-[4-(benzhydryloxy)benzoyl]benzoic acid DM8MVE9 Discovery agent N.A. Investigative [4]
4-[4-benzyloxy)benzoyl]benzoic acid DMQ9IN4 Discovery agent N.A. Investigative [4]
5-(4-Chloro-phenyl)-1-methyl-piperidin-2-one DMJKAF0 Discovery agent N.A. Investigative [6]
5-(4-Chloro-phenyl)-1-methyl-piperidine-2-thione DMQB1UI Discovery agent N.A. Investigative [6]
GP515 DMRUIX3 Discovery agent N.A. Investigative [8]
LY-266111 DMX5H3T Discovery agent N.A. Investigative [6]
{4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid DMX53OY Discovery agent N.A. Investigative [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Investigative Drug(s)

The Drug-Metabolizing Enzyme (DME) Role of This DTT

DTT DME Name Steroid 5-alpha-reductase 1 (SRD5A1) DME Info
Gene Name SRD5A1
3 Approved Drug(s) Metabolized by This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Oxymetholone DMFXUT8 Aplastic anemia 3A70 Approved [9]
Testosterone cypionate DMC1TEV Testosterone deficiency 5A81.1 Approved [10]
Testosterone enanthate DMB6871 Testosterone deficiency 5A81.1 Approved [10]
------------------------------------------------------------------------------------

References

1 Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol. 2002 Sep;54(3):283-94.
2 Synthesis of 8-chloro-benzo[c]quinolizin-3-ones as potent and selective inhibitors of human steroid 5alpha-reductase 1. Bioorg Med Chem Lett. 2000 Feb 21;10(4):353-6.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013228)
4 Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
5 Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1. J Med Chem. 2000 Oct 5;43(20):3718-35.
6 Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11.
7 Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5.
8 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2. J Med Chem. 1997 Mar 28;40(7):1112-29.
9 Androgen physiology. Semin Reprod Med. 2006 Apr;24(2):71-7.
10 Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).